drugset / Trial / NCT03405155
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Phase 2
Completed
26 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2018-01-17
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |